Recent developments highlight ongoing clinical progress, regulatory designations, financial results, and corporate activities for Quoin Pharmaceuticals.

• Quoin Pharmaceuticals reported third quarter 2026 financial results, including a net loss of approximately $4.9 million and strong liquidity with cash and short-term investments totaling over $34 million as of September 30, 2026 [N1][S2].
• The company received FDA's conditional acceptance of the brand name QYLEKI for QRX003 [N2].
• Quoin Pharma launched a Phase 2 study of QRX003 in Peeling Skin Syndrome following FDA clearance [N4].
• The company received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for QRX003 in treating Netherton Syndrome [N6].
• Lucid Capital Markets initiated coverage of Quoin Pharmaceuticals with a buy recommendation [N7].
• Quoin updated on a Type C meeting with the FDA for QRX003 in Netherton Syndrome and is on track to initiate a Phase 3 trial in 2026 [N8].

The company has achieved multiple regulatory designations for QRX003, including orphan drug status in the US, Europe, and Japan, and FDA Fast Track and Rare Pediatric Disease designations, which may facilitate regulatory review and market exclusivity. Progression through Phase 2 and Phase 3 clinical trials provides data on the therapeutic potential of QRX003 for rare skin diseases with high unmet medical need. Strong liquidity as of Q3 2026 supports ongoing clinical development activities. Clinical data releases and regulatory milestones have generated investor interest and capital raises to fund operations.

Quoin Pharmaceuticals has a limited operating history and has incurred significant losses without generating revenue from product sales. The company relies heavily on third parties for clinical trials and manufacturing, which may introduce delays or quality issues. Regulatory approvals depend on clinical trial outcomes. Restrictive covenants from recent private placements may constrain the company's ability to raise additional capital when needed. Competition in the rare disease space and potential intellectual property challenges pose risks to commercial success. Failure to obtain regulatory approvals or secure adequate reimbursement could materially harm the business.

Quoin Pharmaceuticals' moat is primarily based on its focus on rare dermatological diseases with limited existing treatment options, supported by regulatory orphan drug designations that provide market exclusivity benefits. The company's proprietary formulation QRX003 and its patent portfolio contribute to intellectual property protection. However, the company faces competition from other biotech firms developing treatments for rare skin disorders and must navigate regulatory and clinical development challenges to establish a sustainable competitive position.

• Limited Operating History and Financial Losses: The company has a limited operating history and has incurred significant losses since inception, with no revenue from product sales, which increases the risk of continued financial instability and dependence on external financing.
• Regulatory and Clinical Development Risks: Success depends on positive outcomes from preclinical and clinical studies, regulatory approvals, and maintaining orphan drug designations. Delays or failures in clinical trials or regulatory processes could materially harm the business.
• Capital Raising and Financing Constraints: The company must raise additional capital to fund operations but faces restrictive covenants from recent private placements that may limit financing options until late November 2026, potentially impacting liquidity and operational continuity.
• Reliance on Third Parties: Dependence on third-party contractors for research, clinical trials, and manufacturing introduces risks related to performance, quality, and timelines that could delay development and commercialization.
• Intellectual Property Risks: The company must obtain and protect intellectual property rights to compete effectively. Potential infringement claims or failure to secure licenses could disrupt business operations.
• Market and Competitive Risks: Competition from other biotechnology and pharmaceutical companies developing treatments for rare skin diseases may affect market acceptance and commercial success.
• Legal and Regulatory Risks Related to Being an Israeli Company: Differences in Israeli law and challenges in enforcing U.S. judgments may affect shareholder rights and corporate governance.

• Quoin Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for rare skin diseases, including Netherton Syndrome and Peeling Skin Syndrome.
• The company’s lead product candidate is QRX003, which has received multiple regulatory designations including FDA Rare Pediatric Disease designation, FDA Fast Track designation, and orphan drug designations in the US, Europe, and Japan.
• QRX003 is being developed for treatment of Netherton Syndrome and Peeling Skin Syndrome, with ongoing clinical trials including a pivotal Phase 3 trial and a Phase 2 study.
• The company has received FDA IND clearance to initiate the Phase 2 study of QRX003 in Peeling Skin Syndrome and is on track to initiate the Phase 3 trial for Netherton Syndrome in 2026.
• Quoin Pharmaceuticals has secured conditional FDA acceptance of the proposed brand name QYLEKI for QRX003.
• The company has filed patent applications for QRX003 and novel topical formulations to treat skin diseases.
• Quoin Pharmaceuticals has conducted a private placement financing in October 2025 and August 2026, which includes restrictive covenants affecting additional financing activities.
• As of September 30, 2026, the company reported cash and cash equivalents of approximately $10.1 million, short-term investments of approximately $23.1 million, current assets of approximately $34.4 million, and current liabilities of approximately $4.8 million, resulting in a current ratio of 7.2 and a cash ratio of 6.95, indicating strong liquidity.
• The company reported a net loss of approximately $4.9 million for the quarter ended September 30, 2026.
• Quoin Pharmaceuticals has a limited operating history, has incurred significant losses since inception, and has not generated revenue from product sales.
• The company relies on third parties for compound formulation, research, clinical trials, and manufacturing, which introduces operational risks.
• Quoin Pharmaceuticals faces risks related to regulatory approvals, clinical trial outcomes, intellectual property protection, competition, and the need for additional capital.
• The company is subject to restrictive covenants under its Purchase Agreement that may limit its ability to raise additional financing until late November 2026.
• Quoin Pharmaceuticals is an Israeli company, which introduces certain legal and regulatory risks related to shareholder rights and enforcement of judgments.
• The company has appointed Sally Lawlor as CFO in 2025.
• Quoin Pharmaceuticals has publicly communicated updates on clinical progress, regulatory milestones, and financial results through multiple news releases and SEC filings.